Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy

NCT03776643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Allergic Rhinoconjunctivitis to Birch Pollen
With a Positive Skin Prick Test to Birch Pollen

Interventions

DRUG: ILT-101 ld-(IL2)

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]